First Investment: 2021
Finding new drugs to treat disease requires understanding the exact changes in gene and protein expression that make patients sick. Relation Therapeutics is using active graph machine learning, a mathematical method adapted from consumer social networking, to study data from individual human cells to find the most promising ways to treat disease, starting with osteoporosis.
News & Insights
News
Deep Tech Opportunities Report
DCVC DTOR 2025: Introduction
Deep Tech Opportunities Report
DCVC DTOR 2024: TechBio is emerging as the data-centric, AI-native counterweight to biotech
News
Relation Therapeutics partners with GSK in history-making collaboration to create new treatments for fibrosis and osteoarthritis
Deep Tech Opportunities Report
DCVC DTOR 2024: In the AI race, data will emerge as the critical asset
News
DCVC leads $35 million financing to help UK TechBio leader Relation Therapeutics to seek new treatments for complex diseases
In The Media
Endpoints News
Exclusive: Relation, Deerfield agree to form new companies from discovered drug targets
Relation
Bloomberg
Novartis Strikes Deal With UK Biotech for Up To $1.7 Billion
Relation
Forbes
How Collaborations Are Helping London Biotechs Find A Route To Market
Relation
Endpoints News
'It's the biology, stupid': Relation and GSK team up on fibrosis, osteoarthritis
Relation
Endpoints News
‘ChatGPT for DNA’: Relation nabs $35M, with Nvidia backing, for osteoporosis work
Relation
Clarivate
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
Relation
Explore Companies
Sidewinder Therapeutics
Advancing precision bispecific antibody-drug conjugates to treat cancer
Newleos Therapeutics
Transforming the treatment of anxiety and other neuropsychiatric disorders
Grove Biopharma
Putting protein-like drugs inside cells to fight cancer and neurodegeneration
Syntax Bio
Programming stem cells to differentiate into desired cell types, faster